Intravitreal anti-vascular endothelial growth factor (VEGF) therapy in patients with diabetic macular edema (DME) is associated with meaningful improvements in vision and vision-related quality of life, which are more pronounced for near-body activities than for distant activities [1]. Here, VEGFA is linked to diabetic macular edema.